Please note that this website uses cookies necessary for the functioning of our website, cookies that optimize the performance, to provide social media features and to analyse website traffic.

Adjuvanted (sic) Trivalent Influenza Vaccine:Seqirus

I have been invited twice by my GP surgery to have ‘flu vaccination.

I asked for details. “I should be grateful to know which vaccine I would receive and its contents.  Also - I  have in mind a surgeon whom I trained.  Some doctors at Torbay Hospital resisted 'flu vaccination first time around, but it was insisted upon.  c. 8 years ago.  This doctor/surgeon suffered a neural injury as a result, with a permanent effect.  My diagnosis, without examination - ?neuralgic amyotrophy.  I have seen this following ?tetanus immunization or ?toxoid administration for instance.  (edited)  Added - there were 'hot spots' of 'lock jaw'.  Daccombe was one, and that patient was a market gardener in that hamlet.  The good local GP promoted vaccination against tetanus.

I am sorry to add to your work but like to know what might be injected into me.  I add that I have not had the 'flu jab' for at least 10 years and have been lucky to 'escape' the seasonal A or B. My wife and her brother have never suffered 'flu!  This is food for thought. Many thanks David Halpin

Answer “The flu jab you would get is Seqirus adjuvanted trivalent influenza vaccine. Hope this helps.”

Seqirus is part of CSL Limited (ASX:CSL), headquartered in Melbourne, Australia. The CSL Group of companies employs more than 20,000 people with operations in more than 60 countries.

Quote - In October 2014, Novartis announced its intention to sell its influenza vaccine business, including its development pipeline, to CSL for $275 million. CSL merged it into its BioCSL operation.[11] In November 2015, BioCSL rebranded the combined business with Novartis Influenza Vaccines as Seqirus creating the world's second largest influenza vaccine company.[12] Completed in 2018, Seqirus's Holly Spring, NC, plant was funded with $59 million from the U.S. government.[13]

The trivalent influenza vaccine with adjuvant – 9.75 mg of squalene + several emulsifiers - >>

This text is in each ampoule I believe. In achieving ‘informed consent’, is each adult subject, or the parent of a child given this? Without informed consent, would this be a criminal assault?

Quotes -

If you get any side effects,talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Flu is a disease that can spread rapidly and is caused by different types of strains that can change every year. Therefore, this is why you might need to be vaccinated every year.

Do not use Adjuvanted Trivalent Influenza Vaccine (Surface Antigen, Inactivated)-if you are allergic (hypersensitive) to the active substances, to any of the ingredients of Adjuvanted Trivalent Influenza Vaccine (Surface Antigen, Inactivated), to eggs, to chicken proteins, such as ovalbumin, to kanamycin and neomycin sulphate, to formaldehyde, cetyltrimethyl ammonium bromide (CTAB) and to hydrocortisone(For information about the other ingredients of Adjuvanted Trivalent Influenza Vaccine (Surface Antigen, Inactivated) see section 6 “Contents of the pack and other information”) or -if you have had an anaphylactoid reaction to previous influenza vaccination.- if you have an illness with a high temperature or acute infection, the vaccination shall be postponed until after you have recovered.

Read - Warnings and precautions via the above link

Further quotes -

4. Possible side effectsLike all medicines, Adjuvanted Trivalent Influenza Vaccine (Surface Antigen, Inactivated) can cause side effects, although not everybody gets them.More mild post-immunisation reactions were reported with Adjuvanted Trivalent Influenza Vaccine (Surface Antigen, Inactivated) compared to non-adjuvanted influenza vaccines.During clinical trials, the following side effects have been observed:

Frequencies estimated as very common(affects 1 or more users in 10):•headache•muscular pain (myalgia)•tenderness, pain at injection site, fatigueFrequencies estimated as common (affects 1 to 10 users in 100):•nausea, diarrhoea, vomiting •sweating•joint pain (arthralgia)•fever, generally feeling unwell (malaise), shivering•local reactions: redness, swelling, bruising (ecchymosis), hardness (induration) around the area where the vaccine is injectedFrequency estimated as uncommon (affects 1 to 100 users in 1000):•rashMost reactions are mild or moderate and resolve spontaneously within 1 to 2 days.

Next to the above common side effects, the following side effects occurred after the vaccine came on the market:•reduction in the number of certain types of particles in the blood called platelets; a low number of these can result in excessive bruising or bleeding (thrombocytopenia); swelling of the glands in the neck, armpit or groin (lymphadenopathy)•asthenia, Influenza-like Illness (ILI)•swelling, pain and redness at the injection site extending to more than 10 cm and lasting more than one week (Injection site cellulitis-like reaction)•extensive swelling of injected limb lasting more than one week•allergic reactions:- sudden fall in blood pressure (anaphylaxis) that in rare cases can lead to failure of the circulatory system to maintain adequate blood flow to the different organs (shock) - swelling most apparent in the head and neck, including the face, lips, tongue, throat or any other part of the body (angioedema)•pain in the extremity, muscular weakness •pain situated on the nerve route (neuralgia), anomalies in the perception of touch, pain, heat and cold (paraesthesia), fits (convulsions), fainting, feeling faint (syncope, presyncope),neurological disorders that may result in stiff neck, confusion, numbness, pain and weakness of the limbs, loss of balance, loss of reflexes, paralysis of part or all the body (encephalomyelitis, neuritis, Guillain-Barré Syndrome)•skin reactions that may spread throughout the body including itchiness of the skin (pruritus, urticaria), rash•severe skin rash (erythema multiforme)•blood vessel inflammation which may result in skin rashes (vasculitis) and in very rare cases in temporary kidney problems

Reporting of side effects If you get any side effects,talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card SchemeWebsite: or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

The adjuvant is: MF59C.1: 9.75 mg squalene;1.175 mg polysorbate 80; 1.175 mg sorbitan trioleate; 0.66 mg sodium citrate; 0.04 mg citric acid and water for injections.

Quote - “Immunologic adjuvants are substances, administered in conjunction with a vaccine, that stimulate the immune system and increase the response to the vaccine. Squalene is not itself an adjuvant, but it has been used in conjunction with surfactants in certain adjuvant formulations.[14]

An adjuvant using squalene is Seqirus' proprietary MF59, which is added to influenza vaccines to help stimulate the human body's immune response through production of CD4 memory cells. It is the first oil-in-water influenza vaccine adjuvant to be commercialized in combination with a seasonal influenza virus vaccine. It was developed in the 1990s by researchers at Ciba-Geigy and Chiron; both companies were subsequently acquired by Novartis.[14] Novartis was later acquired by CSL Bering and created the company Seqirus. It is present in the form of an emulsion and is added to make the vaccine more immunogenic.[14] However, the mechanism of action remains unknown. MF59 is capable of switching on a number of genes that partially overlap with those activated by other adjuvants.[15]How these changes are triggered is unclear; to date, no receptors responding to MF59 have been identified. One possibility is that MF59 affects the cell behavior by changing the lipid metabolism, namely by inducing accumulation of neutral lipids within the target cells.[16] An influenza vaccine using MF59 as an adjuvant was approved for use in the US in people 65 years of age and older, beginning with the 2016-2017 flu season.[17]

Me. DSH. I recall studying the outbreak of swine ‘flu’ in military recruits at Fort Dix in early 1976. It was limited to the camp, one of over 200 recruits were affected, and one died. Detailed. Note the spider’s web

Quotes emphasising risk of Guillain-Barré/tranverse myelitis. Several ‘natural causes’. If high thoracic level > paralysis of respiratory muscles and risk of death without mechanical ventilation/

27 – HEW begins to prepare legislation authorizing indemnification of the manufacturers against all claims other than those based on negligence

13 – Sencer makes a conference call to outside experts; reports preliminary data on the association of Guillain-Barré with the vaccine, and seeks their opinions; consensus is that program should not be halted

14 – CDC issues press release on Guillain-Barré; says that 54 cases in 10 states have thus far been reported, and of the 54, 30 received shot anywhere from one to thirty days before onset of symptoms

17 – Kennedy subcommittee holds a hearing; chairman says program is dead, and Cooper agrees that it would be difficult to get program started again, if and when such is recommended; Foege estimates incidence of Guillain-Barré in vaccinated group is about four times greater than normal

18 - CDC formulates new Informed Consent forms, incorporating a warning on the possibility of the vaccinee contracting Guillain-Barré

17 – Millar sends notice from CDC to all project areas explaining moratorium; Dr. Phil Brachman writes state epidemiologists, asking that they survey all Guillain-Barré reported after September 1



If you have studied the above texts, would you as a mother or father, or both of you, consent to your child receiving a ‘flu vaccine. This from Public Health England’s web site. Slide presentation for ‘health practitioners’. (This will include pharmacies)

Flu vaccine effectiveness

efficacy varies from one season to the next. Overall efficacy is calculated at between 30-60% for adults aged 18 to 65 years

lower efficacy in elderly although immunisation is shown to reduce incidence of severe disease including bronchopneumonia, hospital admissions and mortality

provisional end-of-season adjusted vaccine effectiveness (VE) estimates for 2019/20 showed an overall VE of 42.7% against all laboratory confirmed influenza

VE was 22.7% in ≥65 year olds and 16.2% for those ≥65 year olds who received the adjuvanted vaccine (aTIV)

VE was 44.5% for 2 to 17 year olds receiving quadrivalent live attenuated influenza vaccine (LAIV)

there is evidence of overall significant influenza VE in 2019/20, most notably against influenza A(H1N1)pdm09, but as seen in the past two seasons, there was reduced VE against A(H3N2).

the new QIVc vaccine provided significant protection for those in the 18-64 age group